Summary We have quantitated the levels of mRNAs in bone marrow samples from patients with multiple myeloma of the mdrl gene (responsible for the Multidrug Resistance phenotype) and for two of the glutathione S-transferase gene. GST-2 and GST-3 (which can also inactivate a wide variety of cytotoxic drugs) and examined the relationship between the levels of expression of these genes and response to subsequent chemotherapy. From a total of 47 patients. 37 were treated with chemotherapy with 34 evaluable for response. Twenty-nine of the patients treated had not received any treatment prior to the marrow sampling while eight had previously received chemotherapy. Patients who failed to respond to initial chemotherapy had significantly higher levels of mdrl than patients who responded (P = 0.01). In the total myeloma patient data set. mRNA levels for mdrl and GST-2 were significantly correlated (Spearman rank correlation coefficient (r) = 0.54. P = 0.0004) as were expression levels of GST-2 with GST-3 (r = 0.43. P = 0.017). GST-3 and mdrl levels were more weekly associated (r = 0.16. P = 0.4). These data would suggest a significant relationship between failure of chemotherapy in multiple myeloma patients and increases in expression of the mdrl gene together with other genes whose products will generate additional mechanisms of resistance to chemotherapeutic agents.
Although a number of cancers initially respond to treatment with chemotherapeutic agents. many are intrinsically resistant or ultimately acquire resistance to a variety of drugs. The phenomenon of multidrug resistance (MDR) which imparts a collateral resistance to a range of drugs which are structurally and functionally unrelated was first demonstrated in vitro and was found to be due to the increased expression of the mdrl gene which encodes a membrane protein. the Pglycoprotein (p-170) (Kartner et al.. 1983 ). This multidrug resistant phenotype is also associated with a decreased accumulation of intracellular drugs due to increased drug efflux (Fojo et al.. 1985) . Multidrug resistant cell lines. particularly those resistant to high concentration of a drug, usually contain an amplified mdrl gene (Gros et al., 1986) . The Pglycoprotein was also found at higher levels in normal tissue of kidney, adrenal, liver and colon . It is believed that the mdrl gene might be implicated in the detoxification of natural compounds since the higher level of expression occurs mainly in organs involved in this process. Also, the location of the protein in these organs is on the lumenal surface of epithelial cells consistent with such an export function (Thiebaut et al., 1987) . However, mammalian cells possess a number of additional pathways for coping with xenobiotics. Other major pathways include the Glutathione S-Transferases, Glutathione Peroxidase, and the diverse group of P450 enzymes which can detoxify many chemically unrelated compounds (Meister, 1988) . Any coordinate overexpression of these additional pathways which have evolved to respond to chemical insults to the cell will also have a significant effect on the response of tumour cells to chemotherapeutic agents.
Multiple myeloma has a response rate of 50-70% to initial chemotherapy either with an alkylating agent (melphalan or cyclophosphamide) or with combination chemotherapy which includes drugs such as doxorubicin and vincristine. However. eventually nearly all patients develop resistance to further chemotherapy and die of the disease. The phenomenon of MDR has been demonstrated in myeloma patients and correlated with response to chemotherapy (Dalton et al.. 1989 : Epstein et al., 1989 .
In this study. we have examined the nature of the relationship between the levels of expression in myeloma marrow samples of the mdrl gene and two Glutathione S-Transferase genes. GST-2 and GST-3.
Materials and metxods
Cell lines In this study. mdrl mRNA levels are expressed relative to an immortalised human T-cell line. CCRF-CEM cells. which is a drug sensitive cell line orginally derived from an acute lymphoblastic leukaemia. Two other cell lines were also employed: the multidrug resistant cell lines. RIOO and R1000I derivatives of CCRF-CEM cells which are resistant to 100 and 1,000 ng ml-i of vinblastine respectively. Both carry amplifications of the mdrl gene and express mdrl mRNA at high levels relative to their parent cell line (Woodcock et al.. 1990 ). The cells were routinely cultured in the Alpha modification of Eagle's minimal essential medium containing 10% new born bovine serum (Flow Laboratories. Australia). For the first 5 days of each month, the resistant cell lines were exposed to their respective concentration of vinblastine (Velbe: Lilly).
Patient population
Forty-seven patients with multiple myeloma were studied. Bone marrow biopsies were examined microscopically to determine the degree of myeloma cell involvement and an aspirate was provided for RNA extraction. Thirteen of the patients had received previous treatment with an alkylating agent (melphalan or cyclophosphamide) and prednisolone. One of these patients also received the VAD regimen (continuous infusion vincristine plus adriamycin with oral dexamethasone) (Barlogie et al., 1984) . Thirty-seven patients received chemotherapy following the bone marrow biopsy. The chemotherapy protocols used are shown in Table I (Chirgwin et al.. 1979) . RNA was dissolved in cold 10 mM NaOH, 1 mM . Clones for GST-2 and GST-3 were isolated from human cDNA libraries (Board & Webb, 1987; Board et al.. 1989) . For the standardisation of RNA levels in each sample, the initial blots were hybridised with an 18S rat ribosomal probe (Woodcock et al.. 1990 ) whereas the later slot blots were probed with a 28S rRNA oligonucleotide probe (Barbu & Dautry, 1989 Table I . Of the 37 patients treated with chemotherapy, two were too early to be assessable for response and one was lost to follow-up. Seven of the 34 assessable patients had received prior chemotherapy and 27 were newly diagnosed patients previously untreated.
Levels of mRNA for the mdrl gene were determined for all myeloma marrow samples presented in Table I . These filters containing total cellular RNA were rehybridised to determine levels of mRNA for GST-2 and, thirdly, for GST-3 when the additional probe became available. Successful estimations for GST-2 were performed with samples from 46 of these 54 samples and, for GST-3, for 39 samples. Values of mRNA levels for mdrl, GST-2 and GST-3 are presented in Figure 2 (A, B and C respectively) for responders and non-responders according to All samples on these filters could be quantitated satisfactorily with the exception of slot c'l with the ribosomal probe in which the recovery of total RNA from the patient sample had been too low.
chemotherapy had significantly higher mdrl mRNA levels than for the 19 responders (Wilcoxon rank sum test. P = 0.011). The same trend was seen amongst the eight samples from the evaluable patients who had received prior treatment where the mdrl levels from the non-responders were all higher than the mdrl levels from the responders (P = 0.025). Similarly, high GST-2 mRNA levels tended to be associated with a failure to respond both in previously untreated and previously treated patients, but the differences were not statistically significant (P = 0.09 and P = 0.12 respectively). possibly due to the small sample sizes involved (24 and four patients respectively). Over the total group of myeloma patients, mdrl and GST-2 mRNA levels were significantly positive correlated (Spearman rank correlation coefficient r = 0.54, P = 0.0004) (Figure 3a) .
There was no apparent association between GST-3 mRNA levels and response to chemotherapy and the correlation of GST-3 with mdrl (r = 0.16. P = 0.4) was weak. However. there was a strong correlation between GST-3 and GST-2 levels (r = 0.43, P = 0.017) (Figure 3b ). There was no apparent correlation of mdrl. GST-2, or GST-3 levels with survival for previously untreated patients. Patients exhibiting mRNA levels above or below the median value were categorised as having high or low levels of expression respectively. Patients with low mdrl values had a median survival of 22 months compared to a median survival of 26 months for the patients in the high mdrl category (P = 0.13, log rank test). Likewise, patients with low and high GST-2 had median survivals of 25 and 22 months respectively (P = 0.6), while patients with low and high GST-3 levels had median survivals of 27 and 21 months (P = 0.2). In addition to the lack of correlation between levels of expression of these genes and survival, there was no correlation between response to initial chemotherapy and survival in this patient group with non-responder having a median survival of 26 months compared with 22 months for responders (P = 0.5). Similar observations with respect to response and survival for this tumour type have been made previously (Joshua et al., 1991) .
We have received more than one marrow sample from only six patients in this series (Table I) Figure 3 Graph of levels of mRNA for a mdrl plotted against the level of GST-2 and b GST-2 against GST- between patients who are responsive and those who are non-responsive to chemotherapy (Epstein et al., 1989) . While this methodology allows the identification of small subpopulations of cells within a tumour which express high levels of the P-glycoprotein, it has been reported to be relatively insensitive for the detection of low levels of overexpression of the mdrl gene (Stow & Warr, 1991) . We have employed RNA slot blotting and hybridisation with labelled probe (Chabner & Gottesman, 1988 (Bradley et al., 1988) . However, lower levels of cross-resistance to alkylating agents have been reported. For instance. in the multidrug resistant Chinese hamster ovary cell line CHtC' which is 180-fold resistant to colchicine, there is a 4 to 15-fold increase in resistance to melphalan (reviewed by Bradley et al., 1988) . However, in other MDR cell types, no collateral resistance to melphalan was found. Prednisolone has not, to our knowledge, been reported to be affected by the MDR phenotype. The majority of our patients received melphalan plus prednisolone as primary chemotherapy (Table I) an enzyme with the ability to inactivate drugs such as melphalan (Dulik et al., 1986) . While our data strongly implicates the GST-2 gene as one likely to be overexpressed together with mdrl (and, in turn, GST-3 overexpressed with GST-2). it is unlikly that these are the only cell stress-related genes which may share similar responses to cellular insults. It should Aw~~~~~~~~~qf% o.1 l be noted that environmental stresses such as heat shock and sodium arsenite exposure as well as hepatectomy increase P-glycoprotein mRNA levels and will confer transient resistance to vinblastine (Chin et al., 1990; Thorgeirsson et al., 1987) . Thus, increased expression of the mdrl gene and hence the development of resistance to a wider variety of chemotherapeutic agents than those to which the tumour has been directly exposed may be part of a cascade of cell stressinducible responses such as those demonstrated in the studies of Scanlon et al. (1989) with cis-platinum resistant tumours. The induction of such a cascade of damage-related gene products might be an event triggered by the chemotherapy. Alternatively, it may be a common event in the evolution of tumours. providing a selective advantage through the permanent activation of responses which normally function only transiently under conditions of toxic or physical insult.
In this relatively small number of myeloma patients. we found that there was no association between response to initial chemotherapy and survival. Similarly, Joshua et al. (1991) have reported that there was no relationship between percentage fall in paraprotein levels and survival. Survival in that study was determined by the attainment of plateau phase disease. It may be that current chemotherapy regimens are selecting (or possibly even inducing) tumour cell subpopulations with more aggressive growth characteristics. We note that. of three patients (#8, #9. and #16) from whom we have estimated mRNA levels for mdrl, GST-2 and GST-3 prior and then subsequent to initial chemotherapy, one of them (#8) showed markedly increased levels of expression of all three genes in the second marrow sample. 
